PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2012 January; 3(1): 3–4.
Published online 2012 January 25.
PMCID: PMC3292885

Histone modification defects in developmental disorders and cancer

Covalent modifications of histone tails by methylation, acetylation and other changes play an important role in the regulation of gene expression, notably in the context of developmental decisions and cell fate. Two reports, including one in the December issue of Oncotarget, describe the use of whole exome sequencing to identify mutations in the histone modifying enzyme EZH2 in Weaver syndrome, a rare developmental disorder characterised by generalised overgrowth, characteristic facial features and intellectual disability [1, 2]. The findings are remarkable because EZH2 has strong credentials as either an oncogene or as a tumour suppressor in a variety of malignancies as a consequence of somatically acquired mutations.

EZH2 is the catalytic component of the polycomb repressive complex 2 (PRC2), which methylates histone H3 lysine 27, resulting in a mark (H3K27me3) that specifies a transcriptionally repressive chromatin environment. PRC2 consists of an additional two core components, SUZ12 and EED, which are required for complete function and stability of the complex. Elevated expression of EZH2 has been reported in a number of epithelial and hematological malignancies and is associated with an adverse prognosis in prostate and breast cancer. Furthermore, overexpression has been causally linked to genomic deletion of microRNA-101 [3]. Consistent with an oncogenic role, monoallelic gain-of-function missense mutations at EZH2 tyrosine 641 have been found in B-cell lymphomas of germinal center origin that synergize with wild type EZH2 to result in increased levels of H3K27me3 [4]. In contrast, the EZH2 mutations seen in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) are inactivating, dispersed throughout the gene, may be monoallelic or biallelic and are associated with an adverse prognosis [5]. The finding of both gain-of function and loss-of-function EZH2 mutations is consistent with models suggesting that a critical balance of polycomb activity is essential for normal stem cell activity, with either loss or gain of polycomb function being potentially tumorigenic [6].

The mutations seen in Weaver syndrome patients are mostly missense substitutions or indels that preserve the reading frame, although three cases with truncating mutations involving the terminal exon were seen. Although not assessed functionally, several Weaver syndrome mutations are identical to some of the somatic changes described in MPN and MDS patients, strongly suggesting that they confer a loss-of-function. Despite this, only two of the 19 EZH2-mutated Weaver syndrome identified by Tatton-Brown and colleagues developed a malignant disorder [1]. Of these, one developed neuroblastoma and acute lymphoblastic leukemia at the age of 13 months and the second developed lymphoma at 12 years. It should be noted however that the eldest case in this series was only 27 years and that the natural history of Weaver syndrome remains under-investigated. It remains to be seen if there is a propensity to develop myeloid malignancies later in life. Clearly though, inherited EZH2 mutations do not strongly predispose to early-onset myeloid malignancies, a fact that at first sight is somewhat surprising given the suggestion that acquisition of somatic EZH2 mutations is an early event in the multistep pathogenesis of these disorders [5]. It will be important to determine if the mutations seen in Weaver syndrome are perhaps a relatively mild subset of mutations seen in MPN and MDS patients. In addition, inactivating mutations in SUZ12 and EED are seen in hematological malignancies [7] and these genes are obvious candidates for EZH2-wild type cases of Weaver syndrome or related overgrowth disorders.

Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1. This gene also encodes a histone methyltransferase, in this case with activity against histone H3 lysine 36. NSD1 is mutated in carcinoma of the upper aerodigestive tract (www.sanger.ac.uk/genetics/CGP/cosmic/) and also fuses to NUP98 in acute myeloid leukemia. Looking more widely, whole exome screens in lymphoma, multiple myeloma, renal carcinoma and other malignancies have identified genes encoding diverse histone modifiers as targets of somatic mutation. Strikingly, several of these (e.g. MLL2, EP300, CREBBP, ASXL1) are also mutated in human developmental disorders thus pointing towards a remarkable and unexpected convergence between somatic and germline genetics.

REFERENCES

1. Tatton-Brown K, Hanks S, Ruark E, et al. Oncotarget. 2011;2:1127–1133. [PMC free article] [PubMed]
2. Gibson WT, Hood RL, Zhan SH, et al. Am J Hum Genet. 2011 Dec 14. [Epub ahead of print]
3. Varambally S, Cao Q, Mani RS, Shankar S, et al. Science. 2008;322:1695–9. [PMC free article] [PubMed]
4. Yap DB, Chu J, Berg T, et al. Blood. 2011;117:2451–9. [PubMed]
5. Ernst T, Chase AJ, Score J, et al. Nat Genet. 2010;42:722–6. [PubMed]
6. Sauvageau M, Sauvageau G. Cell Stem Cell. 2010;7:299–313. [PubMed]
7. Score J, Hidalgo-Curtis C, Jones AV, et al. Blood. 2011 Nov 3. [Epub ahead of print]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC